UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2014
| BIOANALYTICAL SYSTEMS, INC. |
| (Exact name of registrant as specified in its charter) |
| Indiana | 0-23357 | 35-1345024 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
2701 KENT AVENUE WEST LAFAYETTE, INDIANA |
47906-1382 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders
On March 13, 2014, Bioanalytical Systems Inc. (the “Company”) held its annual meeting of shareholders at its corporate offices located at 2701 Kent Avenue, West Lafayette, IN 47906. A total of 5,907,592 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of the matters voted on at the meeting.
| a.) | Two Class II members of the Board of Directors were elected to serve three-year terms ending in 2017 with the following votes cast: |
| Nominee | For | Withheld | Broker Non-Vote | |||
| Richard A. Johnson, Ph.D. | 3,219,578 | 44,838 | 2,643,176 | |||
| Merrill R. Osheroff, Ph.D. | 3,240,583 | 23,833 | 2,643,176 |
| b.) | The appointment of McGladrey LLP as our independent registered public accountants for fiscal 2014 was ratified by the following shareholder vote: |
| For: | 5,843,489 | |
| Against: | 63,143 | |
| Abstain: | 960 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Bioanalytical Systems, Inc. | |||
| Date: March 14, 2014 | By: | /s/ Jacqueline M. Lemke | |
| Jacqueline M. Lemke | |||
| President, Chief Executive Officer | |||